Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations

被引:72
作者
Walsh, Jennifer [1 ]
Ranmal, Sejal R. [2 ,5 ]
Ernest, Terry B. [3 ]
Liu, Fang [4 ]
机构
[1] Jenny Walsh Consulting Ltd, BioCity Nottingham, Pennyfoot St, Nottingham NG1 1GF, England
[2] UCL Sch Pharm, Dept Pharmaceut, 29-39 Brunswick Sq, London WC1N 1AX, England
[3] GSK, Third Ave, Harlow CM19 5AW, Essex, England
[4] Univ Hertfordshire, Sch Life & Med Sci, Dept Pharm Pharmacol & Postgrad Med, Hatfield AL10 9AB, Herts, England
[5] Intract Pharma, 29-39 Brunswick Sq, London WC1N 1AX, England
关键词
UNCOATED MINI-TABLETS; DISINTEGRATING TABLETS; DRUG-DELIVERY; GELATIN CAPSULE; ESOPHAGEAL TRANSIT; SWALLOWING TABLETS; BOLUS CONSISTENCY; YOUNG-CHILDREN; DOSING ERRORS; OPEN-LABEL;
D O I
10.1016/j.ijpharm.2017.07.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selection and design of age-appropriate formulations intended for use in paediatric and geriatric patients are dependent on multiple factors affecting patient acceptability, safety and access. The development of an economic and effective product relies on a balanced consideration of the risks and benefits of these factors. This review provides a comprehensive and up-to-date analysis of oral dosage forms considering key aspects of formulation design including dosage considerations, ease of use, tolerability and safety, manufacturing complexity, stability, supply and cost. Patient acceptability has been examined utilising an evidence-based approach to evaluate regulatory guidance and literature. Safety considerations including excipients and potential risk of administration errors of the different dosage forms are also discussed, together with possible manufacturing and supply challenges. Age appropriate drug product design should consider and compare i) acceptability ii) safety and iii) access, although it is important to recognise that these factors must be balanced against each other, and in some situations a compromise may need to be reached when selecting an age-appropriate formulation. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:547 / 562
页数:16
相关论文
共 158 条
[1]   Scientific Opinion on the re- evaluation of sorbic acid (E 200), potassium sorbate (E 202) and calcium sorbate (E 203) as food additives [J].
Aguilar, Fernando ;
Crebelli, Riccardo ;
Di Domenico, Alessandro ;
Dusemund, Birgit ;
Frutos, Maria Jose ;
Galtier, Pierre ;
Gott, David ;
Gundert-Remy, Ursula ;
Lambre, Claude ;
Leblanc, Jean-Charles ;
Lindtner, Oliver ;
Moldeus, Peter ;
Mortensen, Alicja ;
Mosesso, Pasquale ;
Parent-Massin, Dominique ;
Oskarsson, Agneta ;
Stankovic, Ivan ;
Waalkens-Berendsen, Ine ;
Woutersen, Rudolf Antonius ;
Wright, Matthew ;
Younes, Maged .
EFSA JOURNAL, 2015, 13 (06)
[2]   Compressed orally disintegrating tablets: excipients evolution and formulation strategies [J].
Al-khattawi, Ali ;
Mohammed, Afzal R. .
EXPERT OPINION ON DRUG DELIVERY, 2013, 10 (05) :651-663
[3]   Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups [J].
Aleksovski, Aleksandar ;
Dreu, Rok ;
Gasperlin, Mirjana ;
Planinsek, Odon .
EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (01) :65-84
[4]   Palatability of oral antibiotics among children in an urban primary care center [J].
Angelilli, ML ;
Toscani, M ;
Matsui, DM ;
Rieder, MJ .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2000, 154 (03) :267-270
[5]  
[Anonymous], 2012, GUID PHARM DEV MED P
[6]  
[Anonymous], 2003, Salt and Health
[7]  
[Anonymous], 2006, PAEDIATR PERINAT DRU, DOI [10.1185/146300906X167737, DOI 10.1185/146300906X167737]
[8]  
Aslani A, 2015, J RES MED SCI, V20, P403
[9]  
BABBITT RL, 1991, J DEV BEHAV PEDIATR, V12, P229
[10]   The technologies used for developing orally disintegrating tablets: A review [J].
Badgujar, Bhatu P. ;
Mundada, Atish S. .
ACTA PHARMACEUTICA, 2011, 61 (02) :117-139